Gabapentin Enacarbil is used for managing postherpetic neuralgia in adults and treating moderate-to-severe primary restless leg syndrome in adults. It was first introduced by Azurity Pharmaceuticals Inc in its drug Horizant on Apr 6, 2011.

Gabapentin Enacarbil Patents

Given below is the list of patents protecting Gabapentin Enacarbil, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Horizant	US6818787	Prodrugs of GABA analogs, compositions and uses thereof	Apr 06, 2025	Azurity
Horizant	US8026279	Crystalline form of γ-aminobutyric acid analog	Nov 10, 2026	Azurity
Horizant	US8048917	Prodrugs of GABA analogs, compositions and uses thereof	Nov 06, 2022 (Expired)	Azurity
Horizant	US8114909	Treating or preventing restless legs syndrome using prodrugs of GABA analogs	Apr 11, 2026	Azurity
Horizant	US8686034	Crystalline form of γ-aminobutyric acid analog	Jan 24, 2025	Azurity
Horizant	US8795725	GABA analog prodrug sustained release oral dosage forms	Jun 10, 2029	Azurity

Add above patents to watchlist

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳